贝伐单抗对Lewis肺癌裸鼠血清及移植瘤中血管内皮生长因子A表达的影响

Effects of Bevacizumab on the Expression of VEGF-A of Serum and Subcutaneous Tumor in Nude Mice with Lewis Cancer

关键词:  贝伐单抗  肿瘤  血管内皮生长因子A  Lewis肺癌

Key words:  bevacizumab  tumor  vascular endothelial growth factor-A  Lewis lung cancer

摘要:

目的 检测贝伐单抗对Lewis肺癌裸鼠血清和移植瘤中血管内皮生长因子A(vascular endothelial growth factor-A，VEGF-A)表达的影响。方法 选择♂ BALB/c裸鼠32只，制作Lewis肺癌裸鼠皮下移植瘤模型，随机均分为对照组、贝伐单抗组、顺铂组、联合用药组。给药3周后处死裸鼠，ELISA法检测血清和皮下瘤中VEGF-A表达，取出皮下瘤做病理切片观察血管情况，并用免疫组化方法检测皮下瘤中VEGF-A表达。结果 3个给药组裸鼠血清VEGF-A含量显著低于对照组(P<0.05)。3个给药组裸鼠皮下瘤VEGF-A含量均比对照组低，其中贝伐单抗及联合用药组与对照组之间的差异有统计学意义(P<0.05)。3个给药组的皮下瘤较对照组坏死、血管更少；联合用药组较贝伐单抗组坏死、血管更少；贝伐单抗组较顺铂组的血管更少，但坏死无明显差别。3个给药组皮下瘤VEGF-A阳性数均明显低于对照组(P<0.05)。结论 贝伐单抗能抑制Lewis肺癌生长，可能与抑制血清和皮下瘤VEGF-A表达有关，且顺铂能增强该作用。此外，VEGF-A高表达的裸鼠，其皮下瘤的血管也更丰富。

Abstract:

OBJECTIVE To detect the expression of vascular endothelial growth factor-A(vascular endothelial growth factor-A) in serum and subcutaneous tumors of nude mices with Lewis lung carcinoma cell after intervention by bevacizumab. METHODS Thirty-two male BALB/c nude mices were equally randomed into control group, bevacizumab group, cisplatin group, and bevacizumab combined with cisplatin group after they were transplanted Lewis lung carcinoma cell and appeared subcutaneous tumor. After 3 weeks by administration, the mices were killed, and the expression of VEGF-A was detected by ELISA in serum and transplated tumor, and transplated tumor were maked into pathological section to obverse the vessel, and the expression of VEGF-A in transplated tumor was detected by immunohistochemical method. RESULTS The VEGF-A expression of serum in 3 medication groups was significantly lower than that in control group(P<0.05). The VEGF-A expression of subcutaneous tumors in 3 medication groups was lower than that in control group, the difference between bevacizumab group and control group, and between bevacizumab combined with cisplatin group and control group were significant(P<0.05). According to pathology, the transplant tumor of 3 medication groups had less necrosis and less blood vessels than the controled group. The necrosis and blood vessels of bevacizumab combined with cisplatin group was less than bevacizumab group, and the blood vessel of bevacizumab group was less than cisplatin group, but there was no significance in necrosis between bevacizumab group and cisplatin group. The positive number of VEGF-A of serum subcutaneous tumors in 3 medication groups was less than this in control group, and the whole difference was significant(P<0.05). CONCLUSION Bevacizumab can inhibit the growth of Lewis lung cancer, which is related to bevacizumab reduces the expression of VEGF-A, and cisplatin can enhance the effect. What’s more, the more expression of VEGF-A, the more vessel in subcutaneous tumor.